UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROV	'AL
OMB Number:	3235-0287
Estimated average burd	den
hours per response	0.5

longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

	pe Response														
1. Name and Address of Reporting Person *- Fishman Corey N.				2. Issuer Name and Ticker or Trading Symbol Iterum Therapeutics plc [ITRM]					5	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _X_ Director10% Owner					
(Last) (First) (Middle) C/O ITERUM THERAPEUTICS PLC, BLK 2, FL. 3, HARCOURT CENTRE, HARCOURT ST.				3. Date of Earliest Transaction (Month/Day/Year) 06/23/2021						X Officer (give title below) Other (specify below) Chief Executive Officer					
DUBLIN, L2 2				4. If A	4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person _Form filed by More than One Reporting Person				
(City) (State) (Zip)				Table I - Non-Derivative Securities Acqu						uired, Disposed of, or Beneficially Owned					
1.Title of S (Instr. 3)	Security		2. Transaction Date (Month/Day/Ye	Execution Execut	Deemed cution Date, if nth/Day/Year)			(A) (In	Securities According to Provide According to Provid	of (D) C T	Amount of Sec Owned Following Transaction(s) (Instr. 3 and 4)		C F E o	wnership orm: irect (D) Indirect	Beneficial Ownership
Reminder:	Report on a s	separate line for each	n class of securities b	eneficial	ly owned direc	tly or i	Pers	ons			collection of in			n SEC 1	474 (9-02)
Reminder:	Report on a s	separate line for each		II - Deriv	vative Securit	es Acq	Pers this curr	ons form ently	are not req valid OMB	uired to r control n	espond unles umber.			n SEC 1	474 (9-02)
1. Title of	2. Conversion	3. Transaction	Table 3A. Deemed Execution Date, if	II - Deriv (e.g., 4. Transact Code	vative Securit puts, calls, wa 5. Numbe ion Derivative Securities	es Acq rants r of e (A) or of (D)	Pers this curr uired, D	form form ently ispose , conv Exerci	a are not req valid OMB ed of, or Ben- vertible secur cisable and ate	uired to recontrol neficially Orities) 7. Title a	wned and Amount of ng Securities	8. Price of	9. Number of Derivative Securities Beneficially Owned Following Reported	10. Ownersh Form of Derivativ Security: Direct (I or Indire	11. Natur of Indire Beneficia (Instr. 4)
1. Title of Derivative Security	2. Conversion or Exercise Price of Derivative	3. Transaction Date	Table 3A. Deemed Execution Date, if any	II - Deriv (e.g., 4. Transact Code	vative Securit puts, calls, wa 5. Numbe Corriction Securities Acquired Disposed (Instr. 3, 4	es Acq rants r of e (A) or of (D)	Pers this curr uired, D , options 6. Date Expirat	ispose, conv Exercion Day/Day/	are not rec y valid OMB ed of, or Ben- vertible secur- cisable and ate Year)	eficially O ities) 7. Title a Underlyi	wned and Amount of ng Securities	8. Price of Derivative Security	9. Number of Derivative Securities Beneficially Owned Following	10. Ownersh Form of Derivativ Security: Direct (I or Indire	11. Natur of Indire Beneficia (Instr. 4)

Reporting Owners

	Relationships				
Reporting Owner Name / Address	Director	10% Owner	Officer	Other	
Fishman Corey N. C/O ITERUM THERAPEUTICS PLC, BLK 2 FL. 3, HARCOURT CENTRE, HARCOURT ST. DUBLIN, L2 2	X		Chief Executive Officer		

Signatures

/s/ Corey N. Fishman	06/25/2021
**Signature of Reporting Person	Date

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The shares underlying this option shall vest at a rate of twenty-five percent of the total number of shares on the one-year anniversary of June 23, 2021 and the remaining 75% will vest in equal monthly installments thereafter until June 23, 2025, which to the Proceedings Proceedings of the Procedings Procedure monthly installments thereafter until June 23, 2025, subject to the Reporting Person providing continuous service to the Issuer on each relevant vesting date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.